Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Although uremic osteoporosis is a component of mineral and bone disorder in chronic kidney disease, uremic toxin (UT) concentrations in patients with end-stage kidney disease and bone mineral density (BMD) changes after kidney transplantation have not previously been described. We hypothesized that elevated UT concentrations at the time of transplantation could have a negative impact on bone during the early post-transplantation period. Hence, we sought to determine whether concentrations of UTs (trimethylamine-N-oxide, indoxylsulfate, p-cresylsulfate, p-cresylglucuronide, indole-3-acetic acid, hippuric acid, and 3-carboxy-4-methyl-5-propyl-furanpropionic acid) upon transplantation are predictive markers for (i) osteoporosis one month after transplantation, and (ii) a BMD decrease and the occurrence of fractures 12 and 24 months after kidney transplantation. Between 2012 and 2018, 310 kidney transplant recipients were included, and dual-energy X-ray absorptiometry was performed 1, 12, and 24 months after transplantation. The UT concentrations upon transplantation were determined by reverse-phase high-performance liquid chromatography. Indoxylsulfate concentrations upon transplantation were positively correlated with BMD one month after transplantation for the femoral neck but were not associated with osteoporosis status upon transplantation. Concentrations of the other UTs upon transplantation were not associated with osteoporosis or BMD one month after transplantation. None of the UT concentrations were associated with BMD changes and the occurrence of osteoporotic fractures 12 and 24 months after transplantation. Hence, UT concentrations at the time of kidney transplantation were not predictive markers of osteoporosis or fractures.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696468PMC
http://dx.doi.org/10.3390/toxins12110715DOI Listing

Publication Analysis

Top Keywords

kidney transplantation
16
transplantation concentrations
16
transplantation
15
month transplantation
12
concentrations
9
uremic toxin
8
toxin concentrations
8
bone mineral
8
mineral density
8
kidney disease
8

Similar Publications

The emergence of organoid models has significantly bridged the gap between traditional cell cultures/animal models and authentic human disease states, particularly for genetic disorders, where their inherent genetic fidelity enables more biologically relevant research directions and enhances translational validity. This review systematically analyzes established organoid models of genetic diseases across organs (e.g.

View Article and Find Full Text PDF

This study aimed to develop a predictive model and construct a graded nomogram to estimate the risk of severe acute kidney injury (AKI) in patients without preexisting kidney dysfunction undergoing liver transplantation (LT). Patients undergoing LT between January 2022 and June 2023 were prospectively screened. Severe AKI was defined as Kidney Disease: Improving Global Outcomes stage 3.

View Article and Find Full Text PDF

[The current status of simultaneous liver kidney transplantation in Japan].

Nihon Shokakibyo Gakkai Zasshi

January 2025

Artificial Organ and Transplantation Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo.

View Article and Find Full Text PDF

Experimental model of unilateral ureteral obstruction reproduces key events of chronic kidney disease: From mice to humans.

Methods Cell Biol

September 2025

Renal Physiopathology Laboratory, Department of Nephrology, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Department of Physiology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain. Electronic address:

Chronic kidney disease (CKD) is currently a serious global health problem, due to its high risk of progression, prevalence and mortality. It not only affects the kidneys but also causes multi-organ damage. Moreover, there is no effective pharmacological treatment, and the only available alternatives are dialysis or transplantation, both of which impose a significant financial burden on healthcare systems.

View Article and Find Full Text PDF

Real-world use of terlipressin in cirrhosis and acute kidney injury: frequent use beyond hepatorenal syndrome.

Clin Gastroenterol Hepatol

September 2025

Unit of Internal Medicine and Hepatology, Department of Medicine, University and Hospital of Padova, Padova, Italy. Electronic address:

Background & Aims: Terlipressin is indicated to treat hepatorenal syndrome (HRS)-acute kidney injury (AKI), but is likely used outside this primary indication in clinical practice. We aimed to investigate real-world practice patterns on the use of terlipressin in AKI in cirrhosis.

Methods: International prospective study including patients hospitalized for decompensated cirrhosis.

View Article and Find Full Text PDF